Open AccessEfficacy and outcomes of CYP3A5 genotype-based tacrolimus dosing compared to conventional body weight-based dosing in living donor kidney transplant recipients
Author(s) -
T Yashwanth Raj,
M Edwin Fernando,
N D Srinivasa Prasad,
S Sujit,
K Thirumal Valavan,
T S Harshavardhan,
Arvind Ramanathan
Publication year - 2022
Publication title -
indian journal of nephrology/indian journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.317
H-Index - 24
eISSN - 1998-3662
pISSN - 0971-4065
DOI - 10.4103/ijn.ijn_278_20
Subject(s) - tacrolimus , dosing , medicine , cyp3a5 , adverse effect , pharmacokinetics , urology , renal function , gastroenterology , transplantation , pharmacology , genotype , biochemistry , chemistry , gene
Clinical use of tacrolimus has been challenging due to its narrow therapeutic index and highly variable pharmacokinetics. In this study, we compared patients who received body weight-based tacrolimus dosing pre-transplant (transplanted from 2016 to 2018) with those who received CYP3A5 genotype-based dosing (2018 to 2020).